DC23329 |
LCH 7749944
Featured
|
LCH 7749944 (GNF-PF-2356) is a novel and potent PAK4 with IC50 of 14.93 uM, shows weak activity against other PAK family members. |
|
DC9626 |
Lck Inhibitor |
Lck Inhibitor is a new class of compounds that are potent inhibitors of Lck with an IC50 value of 7 nM.
IC50 Value: 7 nM [1]
Target: Lck
in vitro: Lck Inhibitor (compound 25) exhibited good potency in the T-cell receptor-induced IL-2 secretion assay (I |
|
DC7184 |
Lcl-161
Featured
|
LCL161 is an oral small molecule antagonist of Apoptosis Proteins (IAPs) that sensitizes a subset of tumors from diverse lineages to treatment with cytotoxic therapies. |
|
DC20006 |
LCL521 |
LCL521 is an acid ceramidase (ACDase) inhibitor. LCL521 also inhibits the lysosomal acid sphingomyelinase (ASMase). |
|
DC21225 |
LCS-1 |
LCS-1 is a small molecule that inhibits growth of human lung adenocarcinoma cells harboring mutations in EGFR or KRAS with IC50 of 0.1-1.5 uM. |
|
DC21226 |
LCS-1.28 |
LCS-1.28 is a small molecule that inhibits growth of human lung adenocarcinoma cells harboring mutations in EGFR or KRAS with IC50 of 0.05-1.6 uM. |
|
DC21227 |
LCS-1.34 |
LCS-1.34 is a small molecule that inhibits growth of human lung adenocarcinoma cells harboring mutations in EGFR or KRAS with IC50 of 0.1-1.1 uM. |
|
DC7707 |
LCZ-696
Featured
|
LCZ696 is a first-in-class dual inhibitor of the angiotensin II receptor(AT II receptor) and neprilysin; a novel single molecule comprising molecular moieties of valsartan and NEP inhibitor prodrug AHU377 (1:1 ratio). |
|
DC9394 |
LDC000067
Featured
|
LDC000067(LDC-067) is a highly specific CDK9 inhibitor with IC50 of 32.7 nM for CDK9/cyclin T1; displays 55/125/210/ >227/ >227-fold selectivity for CDK9 versus CDK2/1/4/6/7. |
|
DC7999 |
LDC1267
Featured
|
LDC1267 is a highly selective TAM(Tyro3, Axl and Mer) kinase inhibitor with IC50 of <5 nM/8 nM/29 nM for Tyro3,Axl and Mer respectively. |
|
DC10143 |
LDC-4297
Featured
|
LDC4297 is a novel CDK7 inhibitor. |
|
DC21228 |
LDD1937 |
LDD1937 is a novel potent FLT3 inhibitor with IC50 of 3 nM, displays >170-fold selectivity over JAK2/3, c-MET, IRAK-4. |
|
DC8493 |
NVP-LDE225(Erismodegib)
Featured
|
LDE225 (NVP-LDE225) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human), respectively. Phase 3. |
|
DC7185 |
LDE225 Diphosphate
Featured
|
LDE225 (NVP-LDE225) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human), respectively. Phase 3. |
|
DC20433 |
LDHA-IN-104 |
LDHA-IN-104 is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50 of 0.87 uM, less potent for LDHB (IC50=6.9 uM). |
|
DC21230 |
LDK1229 |
LDK1229 is a novel potent, selective cannabinoid CB1 receptor inverse agonist with Ki of 220 nM. |
|
DC5167 |
Ceritinib(LDK378)
Featured
|
LDK378 is a highly selective ALK inhibitor with IC50 of 2 nM |
|
DC23787 |
LDN 91946 |
LDN 91946 is a selective, uncompetitive ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitor with Ki of 2.8 uM, exhibits no activity against other cysteine hydrolase (UCH-L3, TGase 2, papain and caspase-3).. |
|
DC22459 |
LDN-109657 |
LDN-109657 is a novel SMN2 modulator that increase SMN protein levels in 3813 fibroblasts by twofold at 370 nM.. |
|
DC8231 |
LDN-192960 2HCl
Featured
|
LDN-192960 is a potent and selective inhibitor of haspin (Haploid Germ Cell-Specific Nuclear Protein Kinase). IC50 = 0.010 µm |
|
DC7451 |
LDN-193189 HCl
Featured
|
LDN193189 HCl is a selective BMP signaling inhibitor, inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively, exhibits 200-fold selectivity for BMP versus TGF-β. |
|
DC8034 |
LDN193189 free base
Featured
|
LDN193189 is a selective BMP signaling inhibitor, inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively. |
|
DC7452 |
LDN-211904 |
LDN-211904 is an inhibitor of erythropoietin-producing hepatocellular carcinoma (Eph) receptors. |
|
DC9432 |
LDN-212320
Featured
|
LDN-212320(OSU-0212320) is a glutamate transporter EAAT2 activator; enhances EAAT2 levels by > 6 fold at concentrations < 5 μM after 24 h.
|
|
DC7586 |
LDN-212854
Featured
|
LDN-212854 is a potent and selective BMP receptor inhibitor with IC50 of 1.3 nM for ALK2, about 2-, 66-, 1641-, and 7135-fold selectivity over ALK1, ALK3, ALK4, and ALK5, respectively. |
|
DC7914 |
LDN-214117
Featured
|
LDN-214117 is a potent and selective ALK2 inhibitor with IC50 of 22 nM; > 100 fold selectivity for ALK5; also inhibits BMP6(IC50=100 nM). |
|
DC7610 |
LDN-57444
Featured
|
LDN-57444 is a reversible, competitive proteasome inhibitor for Uch-L1 with IC50 of 0.88 μM, 28-fold selectivity over isoform Uch-L3. |
|
DC22460 |
LDN-75654 |
LDN-75654 is a novel potent SMN2 modulator (EC50=1.8 uM. |
|
DC22461 |
LDN-76070 |
LDN-76070 is a novel potent SMN2 modulator (EC50=8.3 uM. |
|
DC8775 |
LED209 |
LED209 is a potent QseC inhibitor that blocks both norepinephrine- and epinephrine-triggered QseC-dependent virulence gene expression at 5 pM in vitro. |
|